Efpeglenatide

Summary

Efpeglenatide (CHEMBL4650470) is a phase-3 clinical-stage protein; indicated across 3 conditions including obesity disorder and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 3 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650470
Name	Efpeglenatide
Type	Protein
Max phase	3

Also known as: Efpeglenatide, HM-11260C, Hm11260c, HM11260C, Langlenatide, SAR-439977, SAR439977, EFPEGLENATIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	3	MONDO:0011122	EFO:0001073
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
diabetes mellitus	2	MONDO:0005015	EFO:0000400

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	4
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06174779	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
NCT07379333	PHASE3	RECRUITING	A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
NCT03353350	PHASE3	COMPLETED	Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
NCT03496298	PHASE3	TERMINATED	Effect of Efpeglenatide on Cardiovascular Outcomes
NCT03684642	PHASE3	TERMINATED	Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
NCT03713684	PHASE3	TERMINATED	Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
NCT03770728	PHASE3	TERMINATED	Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
NCT01452451	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
NCT02057172	PHASE2	COMPLETED	Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
NCT02075281	PHASE2	COMPLETED	Effect of LAPS-Exendin on Body Weight in Obese Population
NCT02081118	PHASE2	COMPLETED	Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
NCT01093729	PHASE1	COMPLETED	A Study of HM11260C in Healthy Male Subject
NCT02059564	PHASE1	UNKNOWN	A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).